Fmr LLC Pharvaris N.V. Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Pharvaris N.V. stock. As of the latest transaction made, Fmr LLC holds 5,422,393 shares of PHVS stock, worth $114 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,422,393

Previous 5,395,370 0.5%

Holding current value

$114 Million

Previous $84.7 Million 12.66%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$11.83 - $18.66 $319,682 - $504,249	27,023 Added 0.5%	5,422,393 $95.4 Million
Q4 2024 Feb 13, 2025	BUY	$17.87 - $25.01 $3.39 Million - $4.74 Million	189,714 Added 3.64%	5,395,370 $103 Million
Q2 2024 Aug 13, 2024	BUY	$15.67 - $24.59 $198,570 - $311,604	12,672 Added 0.24%	5,205,656 $97.9 Million
Q4 2023 Feb 13, 2024	BUY	$15.2 - $28.05 $30.2 Million - $55.7 Million	1,985,420 Added 61.9%	5,192,984 $146 Million
Q3 2023 Nov 13, 2023	SELL	$14.68 - $21.4 $2.64 Million - $3.84 Million	-179,593 Reduced 5.3%	3,207,564 $66.9 Million
Q2 2023 Aug 11, 2023	BUY	$7.82 - $16.0 $562,406 - $1.15 Million	71,919 Added 2.17%	3,387,157 $51.3 Million
Q4 2022 Feb 13, 2023	BUY	$1.98 - $11.46 $99 - $573	50 Added 0.0%	3,315,238 $37.3 Million
Q1 2022 May 13, 2022	BUY	$15.98 - $19.65 $320,862 - $394,552	20,079 Added 0.61%	3,315,188 $62 Million
Q4 2021 Feb 14, 2022	SELL	$13.28 - $18.0 $235,720 - $319,500	-17,750 Reduced 0.54%	3,295,109 $52.1 Million
Q3 2021 Nov 15, 2021	BUY	$13.14 - $20.97 $717,995 - $1.15 Million	54,642 Added 1.68%	3,312,859 $58.7 Million
Q2 2021 Aug 13, 2021	BUY	$18.05 - $29.59 $58.8 Million - $96.4 Million	3,258,217 New	3,258,217 $60.7 Million

Others Institutions Holding PHVS

# of Institutions

Shares Held

39.2M

Call Options Held

Put Options Held

View Full List

About Pharvaris N.V.

Ticker PHVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,766,000
Market Cap $708M
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...

More about PHVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account